

Antibody-drug conjugate
 Antibody
 Hyperpolarized inert gas
 Protein
 Radioligand
 Small interfering RNA
 Small molecule

Slower pace

In 2022, the US Food and Drug Administration approved 37 novel drugs, down from 50 in 2021 and 53 in 2020.

DRUG NAME	ACTIVE INGREDIENT	MARKETER	INDICATION	MECHANISM OF ACTION
NexoBrid	Anacaulase	Vericel	Eschar removal	Enzyme-based eschar dissolver
1 Briumvi	Ublituximab	TG Therapeutics	Relapsing forms of multiple sclerosis	Unknown
Xenoview	Hyperpolarized xenon-129	Polarean	Evaluation of pulmonary function and imaging	Magnetic resonance imaging
Lunsumio	Mosunetuzumab	Genentech	Relapsed or refractory follicular lymphoma	CD3 binder
2 Sunlenca	Lenacapavir	Gilead Sciences	HIV infections in adults that cannot be successfully treated with other available treatments	HIV-1 antiretroviral agent
3 Krazati	Adagrasib	Mirati Therapeutics	KRAS G12C-mutated non-small-cell lung cancer	Irreversible inhibitor of KRAS G12C
Rezlidhia	Olutasidenib	Rigel Pharmaceuticals	Acute myeloid leukemia with a susceptible isocitrate dehydrogenase 1 mutation	Inhibitor of mutated isocitrate dehydrogenase 1
Tzield	Teplizumab	Provention Bio	Type 1 diabetes	CD3 binder
Elahere	Mirvetuximab soravtansine	ImmunoGen	Ovarian cancer	Microtubule network disrupter
Tecvayli	Teclistamab	Janssen Biotech	Multiple myeloma	CD3 T-cell engager
Imjudo	Tremelimumab	AstraZeneca	Hepatocellular carcinoma	Blocker of cytotoxic T-lymphocyte-associated antigen 4
Lytgobi	Futibatinib	Taiho Oncology	Intrahepatic cholangiocarcinoma	Kinase inhibitor
Relyvrio	Sodium phenylbutyrate and taurursodiol	Amylyx Pharmaceuticals	Amyotrophic lateral sclerosis	Unknown
Omlonti	Omidenedap isopropyl	Santen Pharmaceutical	Glaucoma or ocular hypertension	Prostaglandin E ₂ receptor agonist
Elucirem	Gadopiclemol	Guerbet	Evaluation of lesions with abnormal vascularity using magnetic resonance imaging	Gadolinium-based contrast agent
Terlivaz	Terlipressin	Mallinckrodt	Hepatorenal syndrome	Vasopressin analog
4 Sotyktu	Deucravacitinib	Bristol Myers Squibb	Plaque psoriasis	Tyrosine kinase 2 inhibitor
Rolvedon	Eflapegrastim	Spectrum Pharmaceuticals	Infection prevention in people with nonmyeloid malignancies receiving myelosuppressive anticancer drugs	Binder of granulocyte colony-stimulating factor
Daxxify	DaxibotulinumtoxinA	Revance Therapeutics	Glabellar lines	Acetylcholine-release inhibitor and neuromuscular blocking agent
Spevigo	Spesolimab	Boehringer Ingelheim Pharmaceuticals	Pustular psoriasis flares	Interleukin-36 inhibitor
Xenpozyme	Olipudase alfa	Genzyme	Acid sphingomyelinase deficiency	Exogenous source of the acid sphingomyelinase
Amvuttra	Vutrisiran	Alynham Pharmaceuticals	Polynuropathy of hereditary transthyretin-mediated amyloidosis	RNA interference
Vtama	Tapinarof	Dermavant Sciences	Plaque psoriasis	Aryl hydrocarbon receptor agonist
5 Mounjaro	Tirzepatide	Eli Lilly and Company	Type 2 diabetes	Agonist of glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide1 receptor
Voquezna	Vonoprazan, amoxicillin, and clarithromycin	Phathom Pharmaceuticals	<i>Helicobacter pylori</i> infection	Proton pump inhibitor and antimicrobials
Camzyos	Mavacamten	Bristol Myers Squibb	Obstructive hypertrophic cardiomyopathy	Cardiac myosin inhibitor
Vivjoa	Oteseconazole	Mycovia Pharmaceuticals	Recurrent vulvovaginal candidiasis	14 α -Demethylase inhibitor
Pluvicto	Lutetium-177 vipivotide tetraxetan	Novartis	Metastatic castration-resistant prostate cancer that is positive for prostate-specific membrane antigen	Damage to DNA in cells that express prostate-specific membrane antigen
Ztalmy	Ganaxolone	Marinus Pharmaceuticals	Seizures in cyclin-dependent kinase-like 5 deficiency disorder	γ -Aminobutyric acid type A receptor modulator
Opdualag	Nivolumab and relatlimab	Bristol Myers Squibb	Unresectable or metastatic melanoma	Programmed cell death receptor 1 blocker and lymphocyte activation gene 3 blocker
6 Vonjo	Pacritinib	CTI BioPharma	Myelofibrosis	Kinase inhibitor
Pyrukynd	Mitapivat	Agios Pharmaceuticals	Hemolytic anemia in pyruvate kinase deficiency	Pyruvate kinase activator
Enjaymo	Sutimlimab	Bioverativ USA	Hemolysis in cold agglutinin disease	Binder of complement C1s subcomponent
Vabysmo	Faricimab	Genentech	Wet age-related macular degeneration or diabetic macular edema	Bispecific binder of vascular endothelial growth factor A and angiotensin-2
Kimtrak	Tebentafusp	Immunocore	Unresectable or metastatic uveal melanoma	Bispecific engager of gp100 peptide and CD3 T cells
7 Cibinqo	Abrocitinib	Pfizer	Refractory moderate to severe atopic dermatitis	Janus kinase inhibitor
Quviviq	Daridorexant	Idorsia Pharmaceuticals US	Insomnia	Orexin receptor antagonist

Sources: US Food and Drug Administration, companies. Note: Drugs are shown in reverse chronological order of approval during 2022.